Santaris, now known as RNA-therapeutics, is a Danish biopharmaceutical company specializing in the development of RNA-based medicines. The company was founded in 2003 in Hørsholm, Denmark, by Henrik Ørum and Jørgen Kjems. Santaris gained global recognition for its pioneering work in the field of RNA therapeutics.

The company's headquarters is located in Hørsholm, Denmark. The facility serves as the central hub for Santaris' research and development activities, as well as its administrative functions. The headquarters houses state-of-the-art laboratories, allowing for cutting-edge research and development of RNA-based therapeutics.

Santaris initially focused on developing RNA-targeted drugs for various diseases, including cancer, metabolic disorders, and infectious diseases. The company made significant strides in the development of LNA (Locked Nucleic Acid) technology, which enables the design of highly potent and specific RNA-targeted drugs. On a global scale, Santaris has expanded its presence through partnerships and collaborations.

Notably, the company entered into a strategic collaboration with Roche in 2007, aimed at discovering and developing RNA-based therapeutics. Additionally, Santaris established collaborations with several other pharmaceutical and biotech companies globally. These partnerships have allowed Santaris to leverage its expertise in RNA-based therapeutics and extend its reach to a broader patient population.

In terms of market position, Santaris has gained recognition as a leading player in the field of RNA therapeutics. It has carved a niche for itself by leveraging its innovative LNA platform. The company has been successful in raising significant funding through venture capital investments, further solidifying its position in the market.

Over the years, Santaris has witnessed major events and achievements. In 2014, the company entered into a merger agreement with California-based RNA medicine company, Rib-X Pharmaceuticals. This merger expanded Santaris' product pipeline and strengthened its position in the RNA therapeutics field.

In recent years, Santaris rebranded itself as RNA-therapeutics, reflecting its focus on developing RNA-based medicines. As of the latest information available, RNA-therapeutics continues to advance its RNA-targeted drug development programs and explore potential collaborations to further expand its reach and impact in the field of RNA therapeutics